



FAOPS

2025

The 24th Congress
of the Federation of
Asia and Oceania
Perinatal Societies

*Innovation and Integration: Shaping the future of
Perinatal Care in Asia and Oceania*

ABSTRACT BOOK

NOVEMBER 14-16, 2025
KATHMANDU, NEPAL



www.faops2025.org



FAOPS
Federation of Asia and
Oceania Perinatal
Societies



PESON
Perinatal
Society of Nepal

24th Congress of FAOPS 2025

Organizing Committee



Prof. Dr. Ashma Rana
Organizing Chairperson,



**Prof. Dr. Sunil Raja
Manandhar**
Organizing
Co-Chairperson



Dr. Bina Basnyat
Organizing Secretary



**Prof. Dr. Kalpana
Upadhyay Subedi**
Scientific Committee
Chairperson



**Dr. Shailendra Bir
Karmacharya**
International/National
Correlation, Chairperson



Dr. Sushila Shrestha
Registration Committee
Chairperson



Prof. Dr. Heera Tuladhar
Treasurer



Dr. Bimala Malla
Hospitality Reception & Cultural
Program Committee
Chairperson



**Dr. Shailendra Bir
Karmacharya**
Souvenir Committee, Chairperson



भ्यालि हस्पिटल प्रा. लि.
Valley Hospital Pvt. Ltd.

Putalisadak, Kathmandu | Phone: 01-4520224, 4513091

हामी काठमाडौंको पुतलीसडकमा रहेर यहाँहरू
माझ उत्कृष्ट, विश्वसनीय र मितव्ययि स्वास्थ्य
सेवा प्रदान गर्न प्रतिबद्ध छौं ।

Our Medical Personalities



Dr. Bina

Consultant
Obstetric & Gynecology



Dr. Bimala

Consultant
Obstetric & Gynecology



Prof. Dr. Chanda

Consultant
Obstetric & Gynecology



Dr. Sudha

Consultant
Obstetric & Gynecology



Prof. Dr. Saraswati

Consultant
Obstetric & Gynecology



Dr. Amila

Consultant
Obstetric & Gynecology



Dr. Rajyalaxmi

Consultant
Obstetric & Gynecology



Dr. Ganga

Consultant
Obstetric & Gynecology



Dr. Durga

Consultant
Obstetric & Gynecology



Dr. Sushila

Consultant
Obstetric & Gynecology



Prof. Dr. Mukund

General Surgeon



Dr. Keshari

Consultant
Obstetric & Gynecology



Dr. Sutap

Cardiologist



Dr. Manish

Consultant
Pediatric Surgeon



Dr. Shailendra

Consultant
Pediatrician



Dr. Deep

Consultant ENT-HNS



Dr. Rumina

Consultant
Obstetric & Gynecology



Dr. Chanda

Consultant Physician
Internal Medicine




Dr. Manish

Consultant
General Surgery



Dr. Prekshya

Consultant
Obstetric & Gynecology



Dr. Sabina

Consultant
Dermatologist

Our Medical Services

- ✓ Obstetrics & Gynecology
- ✓ Pediatric
- ✓ General Medicine
- ✓ General Surgery
- ✓ Ear, Nose and Throat
- ✓ Vaccinations
- ✓ Menopausal Clinic
- ✓ Infertility Clinic
- ✓ USG
- ✓ Dermatology
- ✓ Cardiology
- ✓ Psychiatric
- ✓ Endocrinology
- ✓ Orthopaedic
- ✓ Neurology
- ✓ Pathology
- ✓ Pharmacy
- ✓ Ambulance



01-4520224, 9864150673



Putalisadak, Kathmandu



valleyhospital.pltd@gmail.com



For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.

The most advanced, 3rd generation, subunit quadrivalent Influenza vaccine¹⁻³

INFLUVAC[®] TETRA

Influenza vaccine (surface antigen, inactivated)

More Power with Broad Protection[†]



Most advanced, **3rd generation**,
subunit quadrivalent Influenza vaccine
with less impurities¹⁻⁴



Prefilled syringe, ready to use
and convenient⁴



Images shown are not of actual patients and are for representational purpose only

[†] Veisken T, et al. Int J Infect Dis 2020;92:29-37

¹ Centers for Disease Control and Prevention. Quadrivalent Influenza Vaccine. [Internet] [Updated 2019 Nov 6] [Cited 2023 Jan 16]. Available at: <https://www.cdc.gov/flu/prevent/quadrivalent.htm>. ² Shah R et al. Advantages of Subunit Influenza Vaccine: An Overall Perspective. AJPP. 2018; 1(5): 19-28. ³ Wood JM, Williams MS. History of inactivated Influenza vaccines. In: textbook of influenza. Oxford: Blackwell Science 1998, pp. 317-323. ⁴ Influvac Tetra PI, Data on file

Abbreviated Prescribing Information Inactivated Influenza Vaccine (Surface Antigen) IP Influvac 2021 (Suspension for injection) Composition: Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/Victoria/2570/2019 (H1N1)pdm09-like strain/A/Victoria/2570/2019, IVR-215) 15 micrograms HA* A/Hong Kong/2671/2019 (H3N2)-like strain (A/Hong Kong/2671/2019, IVR-208) 15 micrograms HA* B/Washington/02/2019-like strain (B/Washington/02/2019, wild type) 15 micrograms HA* * propagated in fertilized hens eggs from healthy chicken flocks. * Haemagglutinin This vaccine complies with the World Health Organization (WHO) recommendation (southern hemisphere) and competent authority decision for the 2021 season. Indications: Prophylaxis of influenza, especially those who run an increased risk of associated complications. Influvac 2021 is indicated in adults and children from 6 months of age. Vaccination is particularly recommended for the following categories of patients: persons aged ≥ 65 yrs, regardless of their health condition, adults and children with chronic disorders of the pulmonary or cardiovascular systems, including asthma, adults and children with chronic metabolic diseases such as diabetes mellitus, adults and children with chronic renal dysfunction, adults and children with immunodeficiencies due to disease or immunosuppressant medication (e.g., cytostatic or corticosteroids) or radiotherapy, children and teenagers (6 months – 18 years) who receive long-term acetylsalicylic acid containing medication, and might therefore be at risk for developing Reye's syndrome following an influenza infection. Dosage and administration: Adults: 0.5 ml. Pediatric population: Children from 36 months onwards: 0.5 ml. Children from 6 months to 35 months: Clinical data are limited; doses of 0.25 ml or 0.5 ml may be given. For children who have not previously been vaccinated, a second dose should be given after an interval of at least 4 wks. Children less than 6 months: the safety and efficacy of Influvac in children less than 6 months have not been established. No data available. Method of Administration: Immunization should be carried out by intramuscular or deep subcutaneous injection. Contraindications: Hypersensitivity to the active substances, to any of the excipients or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80 or gentamicin. Immunisation shall be postponed in patients/children with febrile illness or acute infection. Warnings and Precautions: As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. Influvac 2019-20 should not be used in circumstances be administered intra-vascularly. Antibody response in patients/children with endogenous or iatrogenic immunosuppression may be insufficient. Pregnancy and lactation: Inactivated influenza vaccines can be used in all stages of pregnancy. Larger datasets on safety are available for the second and third trimester, compared with the first trimester; however, data from worldwide use of influenza vaccine do not indicate any adverse fetal and maternal outcomes attributable to the vaccine. Breastfeeding: Influvac 2019-20 may be used during breastfeeding. Adverse reactions: Common adverse effects (≥1/100, <1/10) have been observed during clinical trials were headache, sweating, arthralgia and local reactions such as redness, swelling, pain, erythema, induration. These reactions usually disappear within 1-2 days without treatment. Other common adverse effects observed are myalgia, fever, malaise, shivering and fatigue. Adverse reactions reported from post marketing surveillance are, next to the reactions which have also been observed during the clinical trials include transient thrombocytopenia, transient lymphadenopathy, allergic reactions, in rare cases leading to shock, angioedema, neuralgia, paresthesia, febrile convulsions, neurological disorders, such as encephalomyelitis, neuritis and Guillain Barre syndrome. Vasculitis associated in very rare cases with transient renal involvement. Generalised skin reactions including pruritus, urticaria or non-specific rash. Based on: Source: Prepared based on full prescribing information dated May 2019 © trademark of the Abbott Biologicals BV, The Netherlands. For full prescribing information, please contact: Abbott India Ltd., Medical Services Division, Floor 16, Godrej BKC, Plot No: C-68, Near MCA Club, BKC, Bandra (E), Mumbai - 400051 © trademark of the Abbott Biologicals BV.

Abbott India Ltd. Floor 16, Godrej BKC, Plot No. C 68, Near MCA Club, Bandra (E), Mumbai - 400051, India